BACKGROUND: Infection with multiple cytomegalovirus (CMV) strains (mixed infection) was reported in a variety of hosts. As the virus genetic diversity in primary CMV infection and the changes over time remain incompletely defined, we examined CMV diversity and changes in diversity over time in healthy adolescent females who participated in a phase 2 CMV gB/MF59 vaccine trial. METHODS:CMV genetic diversity was determined by genotyping of 5 genes-gB (UL55), gH (UL75), gN (UL73), US28, and UL144-in urine, saliva, and plasma samples from 15 study subjects. RESULTS: At the time of primary infection, 5 of 12 (42%) urine samples had multiple virus strains, and 50% of vaccine recipients were infected with gB1 genotype (vaccine strain). Mixed infection was documented in all 15 subjects within 3 months after primary infection, and the majority had different CMV genotypes in different compartments. Changes in genotypes over time were observed in all subjects. CONCLUSIONS: Infection with multiple CMV genotypes was common during primary infection and further diversification occurred over time. Infection with gB1 genotype in vaccine recipients suggests a lack of strain-specific protection from the vaccine. As only 5 polymorphic genes were assessed, this study likely underestimated the true genetic diversity in primary CMV infection.
RCT Entities:
BACKGROUND:Infection with multiple cytomegalovirus (CMV) strains (mixed infection) was reported in a variety of hosts. As the virus genetic diversity in primary CMV infection and the changes over time remain incompletely defined, we examined CMV diversity and changes in diversity over time in healthy adolescent females who participated in a phase 2 CMV gB/MF59 vaccine trial. METHODS: CMV genetic diversity was determined by genotyping of 5 genes-gB (UL55), gH (UL75), gN (UL73), US28, and UL144-in urine, saliva, and plasma samples from 15 study subjects. RESULTS: At the time of primary infection, 5 of 12 (42%) urine samples had multiple virus strains, and 50% of vaccine recipients were infected with gB1 genotype (vaccine strain). Mixed infection was documented in all 15 subjects within 3 months after primary infection, and the majority had different CMV genotypes in different compartments. Changes in genotypes over time were observed in all subjects. CONCLUSIONS:Infection with multiple CMV genotypes was common during primary infection and further diversification occurred over time. Infection with gB1 genotype in vaccine recipients suggests a lack of strain-specific protection from the vaccine. As only 5 polymorphic genes were assessed, this study likely underestimated the true genetic diversity in primary CMV infection.
Authors: Eain Murphy; Dong Yu; Jane Grimwood; Jeremy Schmutz; Mark Dickson; Michael A Jarvis; Gabriele Hahn; Jay A Nelson; Richard M Myers; Thomas E Shenk Journal: Proc Natl Acad Sci U S A Date: 2003-12-01 Impact factor: 11.205
Authors: Shannon A Ross; Zdenek Novak; Sunil Pati; Raj Kumar Patro; Jennifer Blumenthal; Vishwanath R Danthuluri; Amina Ahmed; Marian G Michaels; Pablo J Sánchez; David I Bernstein; Robert W Tolan; April L Palmer; William J Britt; Karen B Fowler; Suresh B Boppana Journal: J Infect Dis Date: 2011-10-01 Impact factor: 5.226
Authors: Bryan T Mayer; Elizabeth M Krantz; David Swan; James Ferrenberg; Karen Simmons; Stacy Selke; Meei-Li Huang; Corey Casper; Lawrence Corey; Anna Wald; Joshua T Schiffer; Soren Gantt Journal: J Virol Date: 2017-05-26 Impact factor: 5.103
Authors: Claire L Townsend; Marianne Forsgren; Karin Ahlfors; Sten-Anders Ivarsson; Pat A Tookey; Catherine S Peckham Journal: Clin Infect Dis Date: 2013-01-18 Impact factor: 9.079
Authors: Ravit Arav-Boger; Rodney E Willoughby; Robert F Pass; Jian-Chao Zong; Won-Jong Jang; Donald Alcendor; Gary S Hayward Journal: J Infect Dis Date: 2002-09-30 Impact factor: 5.226
Authors: Sonja Pötzsch; Nadja Spindler; Anna-Katharina Wiegers; Tanja Fisch; Pia Rücker; Heinrich Sticht; Nina Grieb; Tina Baroti; Florian Weisel; Thomas Stamminger; Luis Martin-Parras; Michael Mach; Thomas H Winkler Journal: PLoS Pathog Date: 2011-08-11 Impact factor: 6.823